Discovery of RMC-0708, an Oral, Bis-Macrocyclic, RAS(ON) Q61H-Selective, Noncovalent, Tri-Complex Inhibitor

Abstract Oncogenic RAS mutations are among the most common drivers of human cancers, with the KRAS Q61H mutation accounting for approximately 7500 new patients each year in the US alone. To target the active, GTP-bound state of the KRAS(ON) Q61H mutant protein directly, we have employed an innovative tri-complex inhibitor (TCI) modality. Herein, we report structure-guided medicinal chemistry efforts that led to the discovery of RMC-0708, an orally bioavailable, bis-macrocyclic, RAS(ON) Q61H-selective, noncovalent, tri-complex inhibitor. Oral administration of a single dose of RMC-0708 resulted in dose-dependent, deep, and durable suppression of tumor RAS pathway activity for up to 72 h in preclinical xenograft models of KRAS Q61H-driven cancers in vivo. RMC-0708 drove deep tumor regressions in several xenograft models of human KRAS Q61H mutant tumors. The discovery of RMC-0708 further underscores the potential of the TCI platform to identify potent and selective noncovalent inhibitors of mutant RAS(ON) with demonstrated selectivity over wild-type RAS.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2026-11-02
DOI
https://doi.org/10.1021/acs.jmedchem.6c02019
Primary Topic
Protein Kinase Regulation and GTPase Signaling
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Discovery of RMC-0708, an Oral, Bis-Macrocyclic, RAS(ON) Q61H-Selective, Noncovalent, Tri-Complex Inhibitor

Anqi Chen, Xing Wei, David C. Montgomery, Abby Marquez et al.
5 links
Journal of Medicinal Chemistry
Protein Kinase Regulation and GTPase Signaling
article

Discovery of RMC-0708, an Oral, Bis-Macrocyclic, RAS(ON) Q61H-Selective, Noncovalent, Tri-Complex Inhibitor

Anqi Chen, Xing Wei, David C. Montgomery, Abby Marquez, Diane F. Eilerts, Zhengping Wang, Adrian L. Gill, Michael Flagella, Micah J. Gliedt, Elena S. Koltun, John E. Knox, Devleena Shivakumar, Aidan C.A. Tomlinson, Julie Probst, Severin K. Thompson, Jessica L. McKinley, Yang Liu, Aaron Seth Tooley, Alexander McNamara, Jingwei Yin, Yu C. Yang, Zhican Wang, Andreas Buckl, Antonio J. López Quiñones, Stephanie Chang
article en

Abstract

Abstract Oncogenic RAS mutations are among the most common drivers of human cancers, with the KRAS Q61H mutation accounting for approximately 7500 new patients each year in the US alone. To target the active, GTP-bound state of the KRAS(ON) Q61H mutant protein directly, we have employed an innovative tri-complex inhibitor (TCI) modality. Herein, we report structure-guided medicinal chemistry efforts that led to the discovery of RMC-0708, an orally bioavailable, bis-macrocyclic, RAS(ON) Q61H-selective, noncovalent, tri-complex inhibitor. Oral administration of a single dose of RMC-0708 resulted in dose-dependent, deep, and durable suppression of tumor RAS pathway activity for up to 72 h in preclinical xenograft models of KRAS Q61H-driven cancers in vivo. RMC-0708 drove deep tumor regressions in several xenograft models of human KRAS Q61H mutant tumors. The discovery of RMC-0708 further underscores the potential of the TCI platform to identify potent and selective noncovalent inhibitors of mutant RAS(ON) with demonstrated selectivity over wild-type RAS.

Journal of Medicinal Chemistry
Revolution Medicines (United States) (US)
Revolution Medicines
Good health and well-being
Openalex Percentile: Top 25%
Protein Kinase Regulation and GTPase Signaling
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon